Should I buy or sell Longeveron stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Longeveron in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LGVN shares. View LGVN analyst ratings or view top-rated stocks .

What is Longeveron's stock price target for 2024?

1 equities research analysts have issued 12-month target prices for Longeveron's stock. Their LGVN share price targets range from $60.00 to $60.00. On average, they anticipate the company's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 3,025.0% from the stock's current price. View analysts price targets for LGVN or view top-rated stocks among Wall Street analysts .

How have LGVN shares performed in 2024?

Longeveron's stock was trading at $13.60 at the beginning of the year. Since then, LGVN shares have decreased by 85.9% and is now trading at $1.92. View the best growth stocks for 2024 here .

Are investors shorting Longeveron?

Longeveron saw a increase in short interest in March. As of March 31st, there was short interest totaling 28,100 shares, an increase of 82.5% from the March 15th total of 15,400 shares. Based on an average trading volume of 876,400 shares, the days-to-cover ratio is currently 0.0 days. Approximately 3.1% of the shares of the company are short sold. View Longeveron's Short Interest .

When is Longeveron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our LGVN earnings forecast .

How were Longeveron's earnings last quarter?

Longeveron Inc. (NASDAQ:LGVN) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($2.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.10) by $0.40. The business earned $0.06 million during the quarter, compared to the consensus estimate of $0.21 million. Longeveron had a negative net margin of 3,020.17% and a negative trailing twelve-month return on equity of 209.14%.

When did Longeveron's stock split?

Longeveron's stock reverse split on Wednesday, March 27th 2024. The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Longeveron IPO?

Longeveron (LGVN) raised $30 million in an IPO on Friday, February 12th 2021. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. served as the underwriters for the IPO.

How do I buy shares of Longeveron?

Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LGVN

Longeveron (LGVN) Stock Price, News & Analysis

→ Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad)

Free LGVN Stock Alerts

$1.92

-0.09 (-4.48%)

(As of 04:37 PM ET)

Compare

Today's Range: $1.90
▼
$2.10
50-Day Range: $1.69
▼
$5.79
52-Week Range: $1.62
▼
$44.00

Volume: 456,641 shs
Average Volume: 1.71 million shs
Market Capitalization: $4.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $60.00

Get Longeveron alerts:

Longeveron MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 3,025.0% Upside
$60.00 Price Target
Short Interest: Healthy
3.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.61
Based on 16 Articles This Week
Insider Trading: Acquiring Shares
$350,000 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.03 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Longeveron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Longeveron has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.10% of the float of Longeveron has been sold short.
Short Interest Ratio / Days to Cover
Longeveron has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Longeveron has recently increased by 82.47%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Longeveron does not currently pay a dividend.
Dividend Growth
Longeveron does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LGVN.

3.1

News and Social Media Coverage

News Sentiment
Longeveron has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for Longeveron this week, compared to 1 article on an average week.
Search Interest
19 people have searched for LGVN on MarketBeat in the last 30 days.
MarketBeat Follows
9 people have added Longeveron to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Longeveron insiders have bought more of their company's stock than they have sold. Specifically, they have bought $350,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
24.34% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.01% of the stock of Longeveron is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Longeveron are expected to remain at ($8.50) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Longeveron is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Longeveron is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Longeveron has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Longeveron Stock (NASDAQ:LGVN)

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

LGVN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LGVN Stock News Headlines

April 13, 2024 | insidertrades.com

Mohamed Wa'el Ahmed Hashad Acquires 10,638 Shares of Longeveron Inc. (NASDAQ:LGVN) Stock

April 18, 2024 | globenewswire.com

Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 17, 2024 | globenewswire.com

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

April 15, 2024 | msn.com

Longeveron stock rallies 85% on Alzheimer's presentation (update)

April 15, 2024 | msn.com

What's Going On With Longeveron Stock?

April 15, 2024 | markets.businessinsider.com

Why Is Longeveron (LGVN) Stock Up 48% Today?

April 15, 2024 | finance.yahoo.com

Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 15, 2024 | globenewswire.com

Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)

April 15, 2024 | investorplace.com

Why Is Longeveron (LGVN) Stock Up 48% Today?

April 14, 2024 | americanbankingnews.com

Longeveron Inc. (NASDAQ:LGVN) CEO Mohamed Wa'el Ahmed Hashad Buys 10,638 Shares

April 14, 2024 | americanbankingnews.com

Longeveron Inc. (NASDAQ:LGVN) Director Buys $75,000.25 in Stock

April 14, 2024 | americanbankingnews.com

Longeveron Inc. (NASDAQ:LGVN) Insider Purchases $250,000.05 in Stock

April 13, 2024 | finance.yahoo.com

Chief Scientific Officer Joshua Hare Acquires 148,936 Shares of Longeveron Inc (LGVN)

April 11, 2024 | globenewswire.com

Longeveron Announces Closing of $5.2 Million Public Offering

April 8, 2024 | globenewswire.com

Longeveron Announces Pricing of $5.25 Million Public Offering

April 8, 2024 | globenewswire.com

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals

April 8, 2024 | investorplace.com

Why Is Longeveron (LGVN) Stock Up 82% Today?

March 19, 2024 | globenewswire.com

Longeveron Announces 1-for-10 Reverse Stock Split

March 1, 2024 | finance.yahoo.com

Longeveron Full Year 2023 Earnings: EPS Misses Expectations

February 29, 2024 | seekingalpha.com

Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript

February 29, 2024 | investing.com

Longeveron LLC earnings missed by $0.81, revenue topped estimates

February 28, 2024 | finance.yahoo.com

Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript

February 27, 2024 | benzinga.com

Recap: Longeveron Q4 Earnings

February 27, 2024 | globenewswire.com

Longeveron Reports Year-End 2023 Results and Provides Corporate Update

February 22, 2024 | benzinga.com

Longeveron Stock (NASDAQ:LGVN) Dividends: History, Yield and Dates

See More Headlines

Receive LGVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LGVN
CUSIP: N/A
CIK: 1721484
Web: www.longeveron.com
Phone: 305-302-7158
Fax: N/A
Employees: 23
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $60.00
High Stock Price Target: $60.00
Low Stock Price Target: $60.00
Potential Upside/Downside: +2,961.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($10.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,410,000.00
Net Margins: -3,020.17%
Pretax Margin: -3,020.17%
Return on Equity: -209.14%
Return on Assets: -136.82%

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 1.50
Quick Ratio: 1.50

Sales & Book Value

Annual Sales: $710,000.00
Price / Sales: 6.93
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.68 per share
Price / Book: 0.73

Miscellaneous

Outstanding Shares: 2,510,000
Free Float: 1,901,000
Market Cap: $4.92 million
Optionable: Not Optionable
Beta: 0.21

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Joshua Michael Hare FACC (Age 61)
M.D., Co-Founder, Chief Science Officer & Chairman
Comp: $74k
Mr. Mohamed Wa'el Ahmed Hashad (Age 62)
CEO & Director
Comp: $781.56k
Ms. Lisa A. Locklear M.B.A. (Age 62)
Executive VP & CFO
Comp: $248.38k
Mr. Paul T. Lehr J.D. (Age 56)
International Executive Director, General Counsel & Secretary
Comp: $554.05k
Dr. Dan Gincel Ph.D. (Age 53)
Senior Vice President of Strategic Collaborations & Scientific Affairs
Dr. Nataliya Agafanova M.D. (Age 54)
Chief Medical Officer
Ms. Elly Ryu (Age 42)
VP & Corporate Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LGVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Longeveron stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Longeveron in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LGVN shares.
View LGVN analyst ratings or view top-rated stocks.
What is Longeveron's stock price target for 2024?: 1 equities research analysts have issued 12-month target prices for Longeveron's stock. Their LGVN share price targets range from $60.00 to $60.00. On average, they anticipate the company's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 3,025.0% from the stock's current price.
View analysts price targets for LGVN or view top-rated stocks among Wall Street analysts.
How have LGVN shares performed in 2024?: Longeveron's stock was trading at $13.60 at the beginning of the year. Since then, LGVN shares have decreased by 85.9% and is now trading at $1.92.
View the best growth stocks for 2024 here.
Are investors shorting Longeveron?: Longeveron saw a increase in short interest in March. As of March 31st, there was short interest totaling 28,100 shares, an increase of 82.5% from the March 15th total of 15,400 shares. Based on an average trading volume of 876,400 shares, the days-to-cover ratio is currently 0.0 days. Approximately 3.1% of the shares of the company are short sold.
View Longeveron's Short Interest.
When is Longeveron's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our LGVN earnings forecast.

How were Longeveron's earnings last quarter?: Longeveron Inc. (NASDAQ:LGVN) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($2.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.10) by $0.40. The business earned $0.06 million during the quarter, compared to the consensus estimate of $0.21 million. Longeveron had a negative net margin of 3,020.17% and a negative trailing twelve-month return on equity of 209.14%.
When did Longeveron's stock split?: Longeveron's stock reverse split on Wednesday, March 27th 2024. The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
When did Longeveron IPO?: Longeveron (LGVN) raised $30 million in an IPO on Friday, February 12th 2021. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. served as the underwriters for the IPO.
How do I buy shares of Longeveron?: Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LGVN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Longeveron (LGVN) Stock Price, News & Analysis

Longeveron MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Longeveron Stock (NASDAQ:LGVN)

LGVN Stock Price History

LGVN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LGVN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™